Hepatitis C

Thursday, October 27, 2016: 12:30 PM-2:00 PM

Room: Poster Hall

Tracks: Adult ID

Presentations:

430

Analysis of HCV Genotype 2 and 3 Variants in Patients Treated with Combination Therapy of Next Generation HCV Direct-Acting Antiviral Agents ABT-493 and ABT-530
Teresa Ng, PhD ; Tami Pilot-Matias, PhD ; Rakesh Tripathi, MS ; Gretja Schnell, PhD ; Thomas Reisch, MS ; Jill Beyer, BS ; Tanya Dekhtyar, MS ; Stanley Wang, MD, PhD ; Federico Mensa, MD ; Jens Kort, MD, PhD ; Christine Collins, PharmD

431

Lessons learned from HIV: creating a hepatitis C linkage to care program
Nancy Glick, MD ; Hilary Armstrong, MPH ; Audra Tobin, BA ; Kristi Allgood, MPH

432

Statistical and Data Mining Analysis to Identify Clinical, Biochemical and Pathological Features of Liver Fibrosis versus Metavir Score in a Cohort of 69106 Chronic Hepatitis C Patients in Egypt
Abubakr Awad, PhD Student in Computer Science ; Mahasen Mabrouk, MD ; Wafaa Elakel, MD ; Wahed Doss, MD ; Tahany Awad, MD ; Samar Kamal, MD

Posters

Poster 2016-09-26.png (361.6 kB)

433

The Risk of Acute Liver Injury with Statin Use in Chronic Hepatitis C Virus Infection
Dana Byrne, MD, MSCE ; Janet P. Tate, ScD ; Kimberly Forde, MD, MHS ; Jay R. Kostman, MD ; Jason Roy, PhD ; Vincent Lo Re III, MD, MSCE

Posters

Byrne_MSCE_Poster_IDWeek_2016_final.pdf (230.1 kB)

434

The Impact of Untreated Hepatitis C Infection on Progression of Renal Decline among Patients with Chronic Kidney Disease
Sara Tartof, PhD, MPH ; Jean Marie Arduino, PhD ; Rong Wei, MA ; Jin-Wen Hsu, PhD ; Kevin Rubenstein, MS ; Haihong Hu, MS ; Michael Horberg, MD, MAS, FIDSA ; Stephen Derose, MD, MSHS ; Carla Rodriguez, PhD

Posters

arduinoj_192102-0001_IDWeek_poster-2_v2.00.pdf (274.4 kB)

435

Electronic Medical Record-Based Liver Fibrosis Staging: Identification of High-Risk Patients at Time of Hepatitis C Diagnosis in the Emergency Department
Julie Schexnayder, DNP, MPH, CRNP ; Ricardo Franco, MD ; Joshua Richman, MD, PhD ; James Galbraith, MD ; Deanne Guthrie, MSCS ; Michael J. Mugavero, MD, MHSc

436

Effectiveness of DAA Regimens in Genotype 1 HIV/HCV Coinfected Patients: An Analysis of the VA National Clinical Case Registry
Debika Bhattacharya, MD, MSc ; Pamela Belperio, PharmD ; Troy Shahoumian, MPH, PhD ; Timothy Loomis, PhD ; Matthew Bidwell Goetz, MD ; Larry Mole, PharmD ; Lisa Backus, MD, PhD

437

Toll-Like Receptor 7 and Interferon Lambda 1 in Patients with Chronic Hepatitis C: Relation to Virus Replication and Liver Injury.
Hoda El Aggan, Professor of Medicine ; Nahla Farahat, Professor of Clinical Pathology ; Nevine El Deeb, Professor of Pathology ; Ahmed Zeid, Assistant Professor of Medicine ; Assem El Sandidi, Lecturer of Medicine

Posters

Dr. Hoda El Aggan poster # 437.pdf (6.8 MB)

438

The Impact of Chronic Kidney Disease on Hepatic and Extra Hepatic Outcomes among Patients with Hepatitis C Infection
Carla V. Rodriguez, PhD ; Jean Marie Arduino, PhD ; Jin-Wen Hsu, PhD ; Rong Wei, MA ; Kevin Rubenstein, MS ; Haihong Hu, MS ; Michael Horberg, MD, MAS, FIDSA ; Stephen Derose, MD, MSHS ; Sara Tartof, PhD, MPH

Posters

arduinoj_192101-0001-IDWeek_Poster-1_v2.00.pdf (351.8 kB)

439

Innovative Linkage to Care for Patients with Hepatitis C Virus Infection
Mariana Castrejon, BS ; Samantha Ramirez, RN ; Jeffrey Klausner, MD, MPH ; Marjan Javanbakht, MPH, PhD ; Sammy Saab, MD, MPH

440

Prevalence of false-positive hepatitis C antibody tests in the National Health and Nutrition Examination Survey (NHANES), 2007-2012
Scott D. Holmberg, MD, MPH, FIDSA ; Anne C. Moorman, BSN, MPH ; Jan Drobeniuc, MD, PhD ; Saleem Kamili, PhD

Posters

Moorman Holmberg IDWeek POster 16-267433_SP_Hep-C_false+.pdf (121.9 kB)

441

Does Adding Ribavirin to Newer DAA Regimens Affect SVR Rates in HCV-Infected Persons in Actual Clinical Settings? Results from ERCHIVES
Adeel Butt, MD, MS ; Peng Yan, MS ; Kristen M. Marks, MD ; Obaid Shaikh, MD ; Kenneth Sherman, MD

Posters

Poster_IDSA2016_RBV or no RBV_FINAL.pdf (478.7 kB)

442

Impact of HCV treatment on liver transient elastography (TE): Prospective data from the CORE hepatitis cohort
Oluwatoyin Adeyemi, MD ; Kerianne Burke, MPH ; Crystal Winston, BA ; Dan Taussig, MPH ; Benjamin Go, MD ; Sonia Vibhakar, PharmD ; Rebecca Golberg, RN ; Gregory Huhn, MD, MPHTM

Posters

IDWeek_FibroscanFINAL.pdf (236.3 kB)

443

Expanded HCV Testing and Linkage to Care: Program Implementation to Overcome Barriers to Engagement in Care
Rebecca Eavou, LCSW ; Ellen Almirol, MPH, MA ; Randee Estes, MT (A.S.C.P.) ; Michelle Taylor, LCSW ; Mai Pho, MD, MPH ; David Pitrak, MD, FIDSA

444

Hepatitis C Treatment Outcomes in People Actively Using Drugs in Dallas, Texas
Jason Gillman, M.D. ; Patrick Clay, Pharm.D, AAHIVP, CPI, CCTI, FCCP ; Jialiang Liu, BS, MS ; Sumihiro Suzuki, Ph.D. ; Deanna Rogers, CCRC ; Lauren Rogers, CCRC ; Gary Sinclair, M.D. ; Gene Voskuhl, M.D.

Posters

HepC-IDSA Poster Final.pdf (386.7 kB)

445

Effects on Liver Stiffness Following Treatment of Hepatitis C with Direct Acting Antivirals as Evaluated by Vibration Controlled Transient Elastography
David Rudd, D.O. ; Hendren Bajillan, MD ; Charles De Comarmond, MD

Posters

Rudd_REV - Final Poster.pdf (146.3 kB)

446

Direct Acting Anti-Viral (DAA) Therapy for Chronic Hepatitis C Virus (HCV) Infection Leads to Regression of Liver Fibrosis, Assessed by Serial Transient Elastography (Fibroscan)
Justin Chan, MD ; Neliswa Gogela, MD ; Hui Zheng, PhD ; Sara Lammert, MPH ; Tokunbo Ajayi, MD ; Zachary Fricker, MD ; Arthur Kim, MD, FIDSA ; Gregory Robbins, MD, MPH, FIDSA ; Raymond T. Chung, MD

Posters

Chan IDSA poster 10-21-2016 FINAL.pdf (287.1 kB)

447

Mutation May Be Important in Second Generation DAA Treatment Failures
Glen Abergel, MD ; Robert H K Eng, MD ; Sandra Kaminski, MS, PA-C ; Alexandra Sonyey, MD

Posters

IDSA 2016 hepC abs poster 9-23-16 draft 3_Final.pdf (334.5 kB)

448

Universal Hepatitis C Screening: Prevalence and Linkage to Care Among Patients Presenting to a Large, Publically Funded Urban Emergency Department
Michael Maurantonio, BS ; Ellie Carmody, MD, MPH ; Svetlana Duvidovich, BA ; Waridibo E. Allison, MBBS PhD ; Ada Rubin, BA ; William Chiang, MD

Posters

Universal Screening for HCV NYU IDWeek 448.pdf (316.2 kB)

449

Predictors of Loss to Follow-Up in Patients with Hepatitis C
Anna Winston, B.S. ; Camilla Graham, MD, MPH ; Mary Lasalvia, MD, MPH

Posters

Winston - ID Week HCV.pdf (485.6 kB)

450

Costs of routine care for chronic hepatitis C virus infection: the case of Illinois Medicaid
Mai T. Pho, MD MPH ; Yue Gao, MPH ; Joshua Salomon, PHD ; Elbert Huang, MD MPH ; Robert Nocon, MHS ; Jake Morgan, MS ; Laura White, PHD ; Benjamin Linas, MD, MPH

451

The Effects of Syringe Exchange Program Access on Hepatitis C Screening Among People Who Inject Drugs
Karli Hochstatter, MPH ; Ryan Westergaard, MD, PhD, MPH ; Timothy Hess, PhD ; Shawnika Hull, PhD ; Mary Peng, MS

Posters

Geographic Determinants of HCV screening poster5.pdf (649.9 kB)

452

Predictors of Neurocognitive Impairment in Hepatitis C Viral Infection
Badr Alhumayyd, MD ; Anya Umlauf, MS ; Scott Letendre, MD ; Allen Mccutchan, MD ; Ronald Ellis, MD, PhD ; Igor Grant, MD ; Ajay Bharti, MD

Posters

452_idwposter.pdf (1.1 MB)

453

Increases in HCV among hospitalized children and the association with substance abuse
Thomas Runge, MD, MPH ; Monica Schmidt, MPH, PhD ; A. Sidney Barritt IV, MD, MSCR ; Ravi Jhaveri, MD, FIDSA, FPIDS

454

Hepatitis C Resistance Associated Variants Among People Who Inject Drugs Treated with Direct-Acting Antiviral-Containing Regimens
Matthew Akiyama, MD, MSc ; Jacqueline Reeves, PhD ; Yolanda Lie, BA ; Linda Agyemang, MPH ; Alain Litwin, MD, MPH, MS

Posters

IDSA 2016 HCV RAVs Poster.pdf (531.5 kB)

455

Increase in Hepatitis C Diagnosis and Opioid-related Deaths in Urban Versus Rural Areas of Louisiana from 2012-2015
Chandra M Becka, MD ; Zack E Bryant, MD ; Dielda Robertson, BS ; Raoult Ratard, MD, MPH & TM, FACPM

Posters

IDWeekHCV2016-FINAL.pdf (576.9 kB)

456

The Implementation of a Novel, Multidisciplinary Hepatitis C Program in an Established HIV Program
Deborah Kahal, MD, MPH ; Janice Heinssen, NP-BC ; Christopher James, PharmD ; Karen Kackenmeister, RN, MSN ; Marci Drees, MD, MS ; Digna Caceres, Admin Asst ; William Mazur, MD

Posters

Kahal et al Poster 58880 ID Week.pdf (812.9 kB)

457

Hepatitis C in the Correctional-Community Continuum of Care: Poor Baseline Linkage Rates and Early Improvement with Care Coordination
Matthew Akiyama, MD, MSc ; Ross Macdonald, MD ; Alison Jordan, MSW ; Fabienne Laraque, MD, MPH ; Devin Columbus, MA ; Michael Maurantonio, BS ; Jessie Schwartz, RN, MPH ; Vinh Pham, MD, PhD ; Ellie Carmody, MD, MPH

458

Rapid Viral Response (RVR) as a Predictor of Treatment Failure in Hepatitis C Virus (HCV) Patients Receiving Ledipasvir and Sofosbuvir (LDV/SOF): A Retrospective Case-Control Analysis
Jeffrey W. Jansen, Pharm.D. ; Travis W. Linneman, Pharm.D. ; Gillian Powderly, Pharm.D.

Posters

ID Week 2016 - Poster 458 - Jansen.pdf (781.1 kB)

459

Effect of Sorafenib on Hepatitis C Viremia in Cirrhotic Patients with Hepatocellular Carcinoma
Jeff Hosry, MD ; Ahmed Kaseb, MD ; Minas P. Economides, MD ; Manal Hassan, MD ; Harrys Torres, MD, FIDSA

460

The Impact of Exclusive Policy on Medicaid Funded Patients Infected with Hepatitis C Virus.
Bertha Ayi, Mb.ChB, FACP, FIDSA, MBA

Posters

IDSA 2016 Hepatitis C poster.pdf (694.5 kB)

461

Effects of Acid-Reducing Agents on Cure Rates for Hepatitis C Patients Treated with Ledipasvir and Sofosbuvir
Cindy Banh, PharmD ; Rebecca Hluhanich, PharmD ; Kathleen Haight, PharmD ; Patricia Poole, PharmD

Posters

Banh_IDWeek_Poster.pdf (1.5 MB)

462

Acute Changes in APRI and FIB-4 Scores During HCV Treatment
Christina Yek, MD ; Carolina De La Flor, MD ; Amit Singal, MD ; Beverley Adams-Huet, MS ; Mamta Jain, MD

Posters

Poster_IDSA_FIB4APRI_vf.pdf (1.1 MB)

463

Identifying Risk factors for Non-Birth Cohort Hepatitis C Testing in a Large Healthcare System
Whitney Nichols, MS ; Alexander Geboy, MS ; Idene Perez, CMA ; Stephen Fernandez, MPH ; Peter Basch, M.D, MACP ; Dawn Fishbein, MD, MS

Posters

ID Week 2016- N-BC Risk Factors Poster Final.pdf (1.1 MB)

465

Does a Detectable Viral Load During Hepatitis C Treatment at Week 4 Predict Virologic Failure in an 8-Week Course of Ledipasvir-Sofosbuvir in Treatment-Naïve Patients with Genotype 1 Infection without Cirrhosis?
Bailey Guest, PharmD ; Charles De Comarmond, MD ; Hendren Bajillan, MD ; John Sanders, MD MPH&TM

Posters

detectable4weekVLharvoni8weekIDWeek2016poster.pdf (666.6 kB)

466

Residential status and transportation are associated with improved retention in care for homeless patients testing positive for HCV
Stephanie Preston, BE ; Frances Lee, BA ; Jane Andrews, MD, MPH

467

Real World Experience Treating HCV in Patients on Opioid Substitution Therapy in Rural Pennsylvania
Tuesdae Stainbrook, DO MPH ; Sarjita Naik, PharmD

Posters

Stainbrook HCV IDWeek 2016 FINAL Poster 467.pdf (211.5 kB)

468

Outcomes of Direct-Acting Antivirals for Hepatitis C in an Indigent Population
Carolina De La Flor, MD ; Christina Yek, MD ; Amit Singal, MD ; Mamta Jain, MD

Posters

IDSA2016_singlecenter_final.pdf (2.5 MB)

469

Sofosbuvir-Based Therapy in Patients with Chronic Hepatitis C Virus Infection and Malignancies – A Prospective Observational Study of 60 Patients
Minas Platon Economides, MD ; Parag Mahale, MBBS ; Jeff Hosry, MD ; Ying Jiang, MS ; Bruno Granwehr, MD ; Harrys Torres, MD, FIDSA

Posters

SOF Poster-ID Week-Final.pdf (472.1 kB)

470

Comparing the Population-Based Frequency of Contraindicated Drug-Drug Interactions between Daclatasvir/Sofosbuvir (DAC/SOF), Grazoprevir/Elbasvir (GZR/EBV), Ledipasvir/Sofosbuvir (LDV/SOF), Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin (OMB/PTV/RTV + DSV ± RBV) and Simeprevir/Sofosbuvir (SIM/SOF) for Treatment of Hepatitis C Monoinfection
Alisha Ahmed, PharmD ; Christopher Schriever, PharmD ; Ronish Amin, PharmD ; Kelly Rose Delehanty, PharmD ; Jenna Yager, PharmD ; Nimish Patel, PharmD

471

Outcome of Chronic Hepatitis C infection in HIV Co-infected with Sofosbuvir containing Regimens in HIV Primary Care Setting with Integration of New York State Department of Health Funding Support
Madhuchhanda Choudhary, MD ; Shelley Gilroy, MD ; John Faragon, PharmD ; Zoe Kingsley, RN ; Joseph Cirabisi, Peer Advocate ; Peter Ells, MD

Posters

56 x 42 ID Week Poster 2016.pdf (537.3 kB)

CME Credits: No CME credit is offered for this session.

ACPE Credits:

ACPE Number:

See more of: Poster Abstract Session